These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20807189)

  • 21. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor biology: clinical implications for ocular treatments.
    Bhisitkul RB
    Br J Ophthalmol; 2006 Dec; 90(12):1542-7. PubMed ID: 17114590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
    Niu G; Chen X
    Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor angiogenesis and anti-angiogenic therapy.
    Kubota Y
    Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I
    Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
    Jin K; Shen Y; He K; Xu Z; Li G; Teng L
    Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular toxicity associated with anti-angiogenic drugs.
    Neves KB; Montezano AC; Lang NN; Touyz RM
    Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic anti-VEGF antibodies.
    Lien S; Lowman HB
    Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor.
    Ferrara N
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):789-91. PubMed ID: 19164810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
    Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
    Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).
    Byrne AM; Bouchier-Hayes DJ; Harmey JH
    J Cell Mol Med; 2005; 9(4):777-94. PubMed ID: 16364190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R; Pagès G
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
    Itatani Y; Kawada K; Yamamoto T; Sakai Y
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-angiogenic alternatives to VEGF blockade.
    Khan KA; Bicknell R
    Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.